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ABSTRACT
EPIDERMAL GROWTH FACTOR-LIKE LIGANDS REGULATE DIMER SELECTION
Jamie S. Rush
November 8, 2018

There are thirteen known endogenous EGF-like ligands. We previously
reported that Betacellulin (BTC) increases ligand-mediated corneal wound healing
more than Epidermal Growth Factor (EGF) [Peterson et al. (2014) IOVS 55(5):287080], although the molecular reason for this is unknown. Despite being better at
promoting wound healing via enhanced cell migration, BTC has reduced receptor
affinity and weaker induction of EGFR phosphorylation. These data indicate that
BTC’s response is not due to enhanced affinity or EGFR-kinase activity. Receptor
phosphorylation and proximity ligation assays indicate that BTC treatment
significantly increases ErbB3 phosphorylation and EGFR:ErbB3 heterodimers. BTC
traffics EGFR at a faster rate than EGF, without noticeable differences in effector
signaling. Thus, we demonstrate that despite both ligands binding to the EGFR, BTC
biases the EGFR to dimerize with ErbB3 and regulates the biological response
through trafficking and unknown effectors.
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
Epidermal growth factor receptor physiology
Epidermal growth factor receptor EGFR is the first receptor discovered of the
four member ErbB family of receptors [1]. All ErbB receptors are receptor tyrosine
kinases that share similarities including transmembrane orientation, structure,
function and mechanism of action. ErbB receptors can form homo- and heterodimers
with all family members and ligand-activated dimers initiate various intracellular
signaling cascades. Each receptor and ligand combination differentially affects cell
physiology, including our model, corneal epithelial homeostasis.
Tissue Development
EGFR has physiological roles that affect mammalian developmental biology as
well as tissue maintenance and regeneration [2]. The critical role EGFR plays in
developmental biology is most evident in EGFR null mice, which have non-viable
embryos or underdeveloped pups that die shortly after birth [3]. The surviving pups
display EGFR knockout specific defects in skin, hair, lungs and brain [4, 5]. Defects of
the skin associated with EGFR inhibition include dermatitis, decreased hair follicles,
randomized direction of follicles, curly hair and shortened-curly vibrissae [6]. Lung
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changes with EGFR knockout mice include type II pneumocyte immaturity and
thickened septae which can lead to pulmonary toxicity and interstitial lung disease
[6]. Defective brain tissue attributed to loss of EGFR is complex but defined by three
critical mechanisms of tissue development; 1) decreased proliferation 2) fewer new
neurons reaching the olfactory bulb and 3) decreased neural cell migration.
Although defective regulation, mutations, and deletions of EGFR reveal the
critical functions of the receptor, there are developmental cues that the role of EGFR
changes during maturation. Fetal tissue ubiquitously expresses EGFR, but decreased
number and density of EGFRs occurs in the subventricular zone in the brain during
animal maturation, consistent with a critical role of EGFR in tissue development
shifting to a less significant role in maintenance and regeneration [7, 8].
Tissue Maintenance and Regeneration
The corneal epithelium is one tissue in which the EGFR plays a critical role in
tissue development and regeneration. Maintaining the structure and preserving the
integrity of the cornea is critical to sustaining quality vision. The clear, convexshaped cornea has two main functions, to focus light into the eye, and to protect the
eye from foreign agents. Anything that compromises the health and integrity of the
cornea will affect the function. Blindness associated with corneal damage is a major
ophthalmic public health problem.

Corneal opacity afflicts 1.9 million people

worldwide according to the World Health Organization [9]. Compromised corneal
epithelium increases the risk of permanent corneal damage, as 28% of corneal
opacity blindness is associated with corneal damage [9]. The most common causes of
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corneal damage are accidental injury, surgery, ulcerations or abrasions caused by
chronic disease or side effects from EGFR inhibitor drug therapy [10]. The cornea is
comprised of three cell layers: the epithelium, stroma and the endothelium (Fig 1).
Two additional layers, the Bowman’s layer and the Descemet’s membrane separate
the individual cell layers. Fibroblast growth factor, keratinocyte growth factor,
interleukins, hepatocyte growth factor and endothelin all promote healing in injured
corneas [11-13]. However, only epidermal growth factor receptor (EGFR) signaling
has been shown to be both necessary and sufficient for corneal wound healing (Fig
1B).

Figure 1. Corneal histology and wound healing
A) Layers of the cornea. The epithelium is the posterior layer of the cornea consisting of
5-7 layers of cells that control the passage of proteins into the stroma. The stroma mostly
consists of highly organized collagen fibers with a sparse number of keratocytes that
refract light, which is necessary for vision. The endothelium is a single layer of cells
responsible for maintaining stromal fluid levels. B) H&E stained cross sections of human
epithelial ablated corneas in various stages of healing.

Excluding the skin, the eye is one of the most accessible organs in the body for
in vivo studies and treatment. Due to its external location, treatments can be as
simple as a drop or an injection, without invasive surgery to monitor changes. Since
the corneal epithelium is the first structure to show trauma after exposure to diverse
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agents [14-17], it is critical to examine corneal epithelium for ocular pharmaceutical
testing. EGFR is in high concentration in the cornea epithelium, and tear fluid
contains EGF at concentrations close to the ligand’s Kd for the receptor [18, 19].
Therefore, studying EGFR mechanics after stimulation or inhibition is critical in
producing new and better drugs for ocular therapies.
ErbB Receptors
Structure and Function
The ErbB family of receptor tyrosine kinases (RTKs) have well-established
roles in developmental biology, tissue homeostasis, and cancer biology [20, 21]. All
four family members [ErbB1 (Epidermal Growth Factor Receptor- EGFR), ErbB2,
ErbB3, and ErbB4] share several structural and functional features including the
size, the transmembrane orientation of the protein, and mechanism of activation.
Each receptor has an extracellular region, a transmembrane helix and an
intracellular region that includes the kinase domain and c-terminal tail [22].
The extracellular region of the ErbB-receptors consists of four domains that
are responsible for ligand binding. Domains I and III are the ligand binding domains
and II and IV are cysteine rich domains that play defining roles in ligand-dependent
transactivation [23-25]. The four domains work in concert, fluctuating between a
“closed” conformation and an “open” conformation that reveals a dimerization arm
from domain II and a tethering arm in domain IV [26, 27]. Without ligand bound, the
receptor prefers the “closed” conformation, which is anchored together by
interactions between the dimerization and tethering arms within the molecule [28].
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While ligand initiates most hetero- and homodimer interactions between receptors,
preformed “inactive” dimers are present in the absence of ligand [28, 29].
Activation of ErbB receptors begins with ligand binding that induces receptor
dimerization, transphosphorylation of cytoplasmic tyrosines, and docking of
downstream effectors to those phosphotyrosines. Once ligand binds the receptor, the
interaction between the arms is broken and the receptor toggles to a stable “open”
conformation. Though the ErbB-receptors are structurally similar, each receptor has
a specific set of ligands that are known to bind and activate the receptors. ErbB2 is
an exception due to its open/active conformation and no known binding ligands [30].
Once the ligand binds domains I and III, the dimerization arm is exposed and the
receptor is then able to either form homo- or heterodimers with the other ErbBfamily members [26, 31]. ErbB-receptors bind directly to each other instead of both
receptors binding the same ligand; this is unique from other receptor tyrosine kinases
[26, 31].
ErbB-family of receptors all consist of a transmembrane domain (TM)
comprised of a single pass -helix. The TM in addition to the role as anchor of the
receptor to the membrane [22], also plays a role in receptor activation and signal
transduction by facilitating dimerization through interactions of GxxxG-like motifs at
the C- and N-terminal ends of the TM [32]. The C-terminal motif regulates receptor
homodimers and the N-terminal plays a critical role in heterodimerization [33].
ErbB3 lacks the C-terminal GxxxG-like domain, which limits the ability to form
homodimers after ErbB3-specific ligand stimulation [34].
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The intracellular region of the ErbB-receptors is comprised of a
juxtamembrane (JM) domain, a kinase domain (KD) and a tyrosine rich C-terminal
tail.

The activated KD facilitates the trans-phosphorylation of the C-terminal

tyrosines after ligand binding and receptor dimerization [35]. Mutation or domain
deletion of the JM causes termination of receptor phosphorylation [36-38],
supporting the JM role in transphosphorylation. The ErbB-receptor KD has an N-lobe
(head) containing a glycine rich loop and a C-lobe (tail) containing an activation loop
and a catalytic loop [39]. The receptors arrange in an asymmetric head-to-tail
conformation, which permits the transphosphorylation of tyrosines in the c-terminal
tail as the C-lobe of one receptor acts as a donor to the N-lobe of the other receptor
[37, 40, 41]. Initially, ErbB3 was thought to be kinase inactive [42, 43]. Later findings
revealed ErbB3 has weak kinase activity [44], which could limit the kinase signaling
potential.

The now activated c-terminal tyrosines can interact with signaling

molecules that have SH2 or PTB domains, which include adaptors, scaffolding
proteins, signal transducers and transcription factors [45].
ErbB Ligands
Structure and Function
The ErbB family of receptors have eleven known ligands that bind to and activate
specific receptors (Fig. 2). EGFR specific ligands include epidermal growth factor
receptor (EGF), transforming growth factor-alpha (TGF-a), amphiregulin (AR), and
epigen (EPN). Some of the EGF-like ligands bind multiple receptors. Heparin binding
epidermal growth factor (HBE), and epiregulin (EPR) and betacellulin (BTC) bind and
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activate both EGFR and ErbB4, neuregulin (NRG) 1 and 2 activate ErbB3 and ErbB4.
NRG 3 and 4 only activate ErbB4. All ErbB ligands contain an EGF domain that
consists of six conserved cysteine residues that form three disulfide bonds during
proper protein folding [46], which facilitates ligand:receptor binding. The consensus
motif sequence for the EGF-like ligands is CX7CX4-5CX10CXCX where X is any amino
acid, the C is cysteine [47]. The presence and spacing of additional specific residues
distinguishes this family from other proteins with EGF domains like Notch and Jagged
I [48, 49].

Figure 2. ErbB family of receptors
The ErbB family of receptors include ErbB1/EGFR, ErbB2, ErbB3 and ErbB4. Each
receptor includes an extracellular region, a transmembrane domain, and an intracellular
region. There are eleven known ligands specific to each receptor including EGF, TGFa, AR,
EPN, HBE, BTC, EPR and NRG 1-4.

EGFR ligands are in a precursor form that is anchored to the plasma
membrane. Juxtacrine signaling occurs between neighboring cells with ligands in this
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confirmation. Anchored ligands contain two extracellular sites specific to certain
ADAM proteins that facilitate cleavage of the ligand. Once the protein is cleaved and
in a soluble form, it then can signal by autocrine or paracrine signaling. Soluble EGFR
ligands range in size from 6 to 11 kDA and utilize the same binding site. Interestingly,
each ligand can induce varying changes in cell physiology including enhanced
development, migration, proliferation and differentiation [2, 19, 50, 51]. The addition
of EGF, TGF and HBE to corneal epithelial cells, which induced greater corneal
wound healing in vivo, reflects a part of the differential roles of EGFR ligands.
Functional redundancy among ligands is indicative in initial studies reporting TGF,
EGF and AR knockout mice do not show any tissue abnormalities [52]. While
treatment with various ligands can illicit various changes in specific cell physiology,
the redundancy in functionality maintains physiology after protein loss or inhibition.
This redundancy can be important for consistency in cell function but is also a
hindrance for receptor specific treatments for disease, like cancer due to
compensatory mechanisms through unencumbered proteins. Further studies will be
necessary to differentiate the degree of effect each ligand has on cell physiology when
compared to the other ligands.
Ligand:EGFR complexes
Signaling events initiated by ligand induced EGFR:ligand complexes give rise
to changes in cell physiology, and can be specific to which ligand is bound to the
complex. While ligand binding to receptor initiates dimerization and activation,
dimer partners and signaling outcomes can vary. Some factors that contribute to the

8

ligand-initiated differences in cell physiology are binding characteristics (ligand and
receptor), phosphorylation patterns of the receptor and trafficking of the receptor.
Ligand specific binding
EGFR ligands bind to the receptor with different affinity. The seven EGFR
ligands are divided into two categories, those with strong affinity and those with
weak affinity. Strong affinity ligands that bind with a lower affinity than 100nM
include EGF, BTC, HBE, and TGF. Weak affinity EGFR ligands that bind at >100nM
include AR, EPR, EPN [53]. Saturation binding studies performed with EGF resulted
in a concave up Scatchard plot, indicative of two binding affinities. There are two
different explanations for this phenomenon: 1) the presence of two different
populations of receptors [54] or 2) negative cooperativity is occurring [55, 56].
In a situation where there are two different populations of receptors, it is
possible to calculate the affinity of each receptor population. The Kd of EGF for the
receptor is ~0.3 nM for high and 2nM for low receptors [18]. When two populations
are present, activation is partially controlled by receptor density, where the higher
density of receptors may accumulate in clathrin-coated pits or lipid rafts creating high
affinity receptors [57]. It has been suggested that low levels of EGF can activate high
affinity receptors and higher concentrations of ligand are needed for activation of low
affinity populations [54]. Research has shown that the EGFRs are at an equilibrium
mixture of all conformations, and the population exhibits binding characteristic that
reflect the distribution of the receptor between high and low affinity forms [58].
External and internal binding of ligand, inhibitors or kinase mutations can shift the
9

conformation equilibrium and shift the receptor from a low to high affinity receptor.
Interestingly, each activated population of receptors induces different signaling
cascades, with the high affinity population contributing the most biologically
compelling signaling events [54, 59].
A negative cooperativity model predicts that binding of the first ligand will
reduce the binding affinity of the second [60]. Previous and recent structural studies
show evidence for a conformational change in the extracellular domain of EGFR upon
ligand binding in Drosophila and in vitro. [56, 60]. Therefore, this model supports the
hypothesis that binding of the first ligand to a receptor would shift the extracellular
domain of a dimer and impede the binding of a second ligand. This confirmation
change would have a similar affinity as a liganded monomer (190-220 pM) whereas
a dual liganded dimer has a lower affinity (2.9 nM) [55]. Supporting the negative
cooperativity model, a study has shown that a single ligand molecule is sufficient to
activate a dimer [61] even though ligand binding facilitates receptor dimerization
[62].
EGFR Signaling Mechanisms
Once activated by ligand, the EGFR:ErbB complex initiates a labyrinth of
signaling events. These events include phosphorylation of downstream proteins as
well as ligand directed trafficking of the complex.

EGFR autophosphorylation

patterns are overlapping but have distinct signaling pathways. The choice of ligand
appears to influence the fate of the receptor complex through binding differences,
ligand size, stoichiometry changes or differential effector interactions.
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Ligand specific phosphorylation
The EGFR contains different tyrosine residues that once phosphorylated,
provide a mechanism for ligand specificity, as each site allows for docking of specific
effector molecules.

Ligand differential phosphorylation was first shown using

phosphopeptide mapping of ErbB4 [63] using mass spectrometry. This study shows
that differential signaling begins with site-specific phosphorylation of the receptor
designated by ligand choice. Ligand specific phosphorylation was further analyzed in
a human epidermoid carcinoma cell line (A431) using EGF and TGF to compare
phosphorylation sites of ligands that activate EGFR [64].

Both ligands induced

similar patterns of receptor tyrosine phosphorylation. However, some sites (Y992,
S1142) varied in the intensity and duration of receptor phosphorylation. In a
separate study, EGF and BTC induced different levels of receptor phosphorylation at
tyrosine sites 1068 and 1173. These differences are associated with changes in
downstream effectors including Shc, Ras and Raf proteins [65].
Ligand specific trafficking
The endocytic pathway can regulate the EGFR activity temporally and
spatially. Trafficking of the EGFR can be altered based on the specific ligand that
binds the receptor. A pivotal study comparing six EGFR ligands demonstrated that
different ligands induced degradation, recycling or both using biochemical and
immunofluorescent assays in HEp2 cells [66]. AR induced both rapid and slow
recycling and EGF induced both slow recycling and degradation. TGF and EPR cause
rapid recycling of the EGFR back to the plasma membrane, allowing it to be activated
11

again. BTC and HBE cause lysosomal degradation of the receptor. One of the main
pathways of EGFR trafficking is clathrin-dependent endocytic trafficking.

The

mechanisms behind ligand differential trafficking are not fully understood, but one
factor that differs between ligands is pH sensitivity. As the receptors travel through
the endocytic pathway, they become involved with multiple compartments that
become increasingly more acidic (Fig 3). Comparing a rapid recycling ligand TGF,
and a slow recycling/degradation ligand EGF, 50% of bound TGF dissociates from
the receptor at a pH of 6.8 compared to 5.0 for EGF [67]. The early endosome has a
pH of ~6.8. When a receptor:ligand complex reaches this compartment, TGF will
dissociate and rapidly recycle, where an EGF bound ligand will stay bound to the
complex to late endosome [68] . The recycling of the receptor also has physiological
effects due to the repeated availability of the receptor after returning to the plasma
membrane, which is reflected where treatment with TGF increases corneal
epithelial migration when compared to EGF [69].
Degradation is another important trafficking event that regulates the receptor
by down regulation. Degradation involves E3 ubiquitin ligase c-Casitas B-lineage
Lymphoma (c-Cbl), which ubiquitylates the EGFR. c-Cbl is known to dock directly to
tyrosine 1045 [70], and once the EGFR is ubiquitylated, it is marked for degradation.
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Figure 3. EGFR Endocytic Pathway- The EGFR undergoes ligand-dependent, clarhrinmediated endocytosis with physiological concentrations of ligand. When ligand binds
the receptor, it dimerizes and the ligand-receptor complex translocate to a clathrin-rich
region. This region invaginates and forms a clathrin-coated pit that pinches off and forms
a clathrin-coated vesicle. Once the clathrin is shed from the vesicle, it fuses with an early
endosome. The early endosome then matures into a late endosome that fuses with the
lysosome where the receptor is degraded (1). The receptor also can be recycled back to
the membrane via rapid (2) or slow (3) pathways.

Betacellulin
History and Physiology
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Since Stanley Cohen’s discovery of EGF in 1962 and subsequent discovery of
EGFR in 1970s, EGFR has been well characterized and described as the prototypical
tyrosine kinase that is critical for tissue development and maintenance. However,
regulation of the receptor is critical to maintaining the health and longevity of the
tissue. Since the initial discovery of EGF, six additional EGFR specific ligands were
found, including BTC [71], first reported as a mitogen in pancreatic  cell tumors.
While BTC has similarities to the other EGFR ligands, it displays some unique
properties [72]. BTC contains two cysteines that can form a fourth disulfide bridge,
in addition to the six-cysteine consensus of the EGF motif. The human membranebound precursor form of BTC contains an Arg-Gly-Asp (RGD) sequence, suggesting an
active role in mediating cell-cell interactions. In in vitro studies, BTC effects cell
proliferation, differentiation, and survival, like other members of the EGF-like ligand
family [72].
BTC is expressed in several tissues, but is found at high levels in the lung,
kidney, and uterus [71]. Not surprisingly, high expression of BTC is also found in the
pancreas where it seems to play a role in islet regeneration [73-75]. BTC is also found
in milk [76], suggesting a role in the mammary gland or involvement in the
development of the gastrointestinal tract of newborn mammals. Accelerated growth
of gastrointestinal organs in rats occurred following the administration of
recombinant BTC in rats [77].

Interestingly, mice lacking BTC had no visible

physiology changes, no overt defects and no changes in viability or fertility [78]. This
supports the functional redundancy within the EGF ligand family.
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Overexpression of BTC has been associated with pancreatic cancer, breast
cancer, endometrium and endometrial cancer [79-81]. While the overexpression of
BTC has been associated with various cancers, a BTC transgenic mouse model with
ubiquitous overexpression of the ligand caused a plethora of phenotypic changes
[82]. The BTC transgenic mice exhibited high early postnatal mortality, reduced body
weight gain, and impaired longitudinal growth. Additionally, there were cataracts
and abnormally shaped retinal layers as well as bone alterations leading to a domeshaped, round head that were hallmarks of BTC transgenic mice.

Pulmonary

pathology primarily characterized by alveolar hemorrhage, thickening of the alveolar
septa, intraalveolar accumulation of hemosiderin-containing macrophages, and
nodular pulmonary remodeling all proved to be the most lethal characteristic of
overexpression of BTC.
An in vitro study indicated BTC as the most efficacious mediator in corneal
wound healing, including cellular migration [19], but in vivo studies revealed EGF as
the most effective corneal wound healing ligand. Clinical studies using EGF as a
treatment of wound healing showed varying results in exogenous treatment with
EGFR ligands [83-86]. This variability could be a result of endogenous ligand
variability, the extent of the wound or the health of the eye and patient.
Binding and Dimerization
The ability of EGF-like ligands to bind to various members of the ErbB receptor
family complicates the study of ligand initiated cross-linked signaling pathways. HBEGF and BTC are the only two EGFR ligands that can induce homodimers of EGFR and
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ErbB4 [72]. Betacellulin is unique because it binds only two receptors, but can
ubiquitously activate all the ErbB family of receptors. While it is well accepted that
BTC binds and activates both EGFR and ErbB4, the activation and binding of ErbB3 is
still controversial. Studies have shown that BTC does not bind nor activate ErbB3 [53,
87, 88], reported weak binding and activation [72, 89], and finally, there is evidence
of robust activation [90, 91]. In general, BTC is not considered an ErbB3 ligand due
to the availability of other receptors for heterodimers when the receptor is activated,
or ligand concentrations are above physiologically relevant levels.
No known ligand binds to the ErbB2 receptor, but it is recognized as the most
likely heterodimer partner to all the ErbB ligands. ErbB2:ErbB3 heterodimers have
been labeled as the most oncogenic pairing of all the ErbB family of receptors due to
their involvement in cell proliferation [89, 91]. Several studies show that ErbB3
cannot be activated without ErbB2, but these studies focus on the ErbB3 specific
ligands Neu1 and Neu2 [92, 93] or cancer biology [94].
Although ErbB3 activation and dimerization is not well understood, the basic
physiology of the ErbB-receptors and ligands is well analyzed. The next step in
understanding the ErbB-family signaling and regulation will include studies that
directly compare each ligand to the others. This study is important to dissecting
which ligands initiate specific physiology changes, and eventually, which pathways
can compensate after ErbB antagonist treatments.
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CHAPTER II1
BETACELLULIN BIASES THE EGFR TO DIMERIZE WITH ERBB3

Introduction
The ErbB family of receptor tyrosine kinases (RTKs) have well-established
roles in developmental biology, tissue homeostasis, and cancer biology [20, 21]. All
four family members [ErbB1 (Epidermal Growth Factor Receptor- EGFR), ErbB2,
ErbB3, and ErbB4] share a number of structural and functional features including
their size, transmembrane orientation of the protein, and mechanism of activation.
Activation of ErbB receptors begins with ligand binding that induces receptor
dimerization, transphosphorylation of cytoplasmic tyrosines, and docking of
downstream effectors to those phosphotyrosines. These activated effectors induce
biochemical changes that lead to modifications in cell biology. Each ErbB family
member is unique in its activating ligands, degree of kinase activity, and cadre of
downstream effectors. These features confer receptor-specific biochemical signals,
which regulate the resulting cell biology.
Receptor specific ligands initiate ErbB RTK signaling. There are 13 known
ligands for the ErbB family of proteins, each encoded by a distinct gene [95]. These

1

Reprinted with permission of the American Society for Pharmacology and Experimental
Therapeutics
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ligands differ in their tissue distribution as well as their rates of association and
dissociation to each receptor. Not only do ligands drive the specificity of
receptor:effector interactions, but also the duration and magnitude of effector
response through differences in membrane trafficking [96, 97]. Ultimately, the ligand
specific mechanisms influence the cellular and physiological responses.
Despite the appreciation that ligands can induce receptor-specific signaling
events, the molecular basis for these differences are not always clear due to the
intrinsic barriers to ligand analysis. Knockdown of the EGFR results in embryonic
lethality in mice, or death shortly after birth, highlighting its role in embryonic
development [98]. In contrast, mice engineered to individually knock out epidermal
growth factor (EGF) [52], transforming growth factor-[99], epigen [100], heparin
binding-EGF [78], betacellulin (BTC) [78], or amphiregulin [52] reveal no lethal
ligand-specific phenotypes and all mice were viable and fertile. More subtle
phenotypes include minor defects, such as altered epithelial tissue homeostasis,
mammary tissue development, or a “wavy” phenotype of the hair [101]. The distinct
knockout phenotypes indicate ligand-specific roles in tissue development and
homeostasis. Absence of lethality when a single ligand is knocked out is consistent
with functional redundancy among the ligands for the EGFR’s most critical functions.
While the overlapping roles of the ligands are likely beneficial to animals, analysis of
the physiological contributions of individual ligands is difficult. In order to
circumvent the limitations of in vivo analysis we, like many others, have turned to cell
biology and biochemical assays to understand ligand-specific signaling.
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Among the endogenous EGFR ligands, BTC is one of the most poorly
understood. It was first identified as a secreted growth factor from pancreatic -cell
insulinomas [71, 102], and has been implicated in a number of physiological
processes, including -cell proliferation [74], keratinocyte proliferation [103], and
angiogenesis [104]. In endometrial, liver, and pancreatic cancers, BTC levels are
elevated [79, 80, 105]. BTC is a dual-specificity ligand that binds both EGFR and
ErbB4 [106, 107]. It has been argued that BTC also binds ErbB3 [108]. The most
compelling evidence for this comes from 32D myeloid progenitor cells that lack
endogenous ErbB RTKs. When ErbB2 and ErbB3 are exogenously expressed, there is
ErbB2 and ErbB3 tyrosine phosphorylation and increased

3H-thymidine

incorporation (DNA synthesis) [91]. However, a more systematic analysis used ErbB
RTKs expressed individually or in pairs; these studies demonstrated that measurable
binding of BTC only occurs when EGFR and ErbB4 are expressed [53].
BTC-null mice are viable and exhibit no overt phenotypes or problems with
fertility; however, the life span of these mice is reduced [78]. While the lack of BTC
demonstrates a positive role in cell biology, overexpression of BTC causes abnormal
hair follicle development [104], increased glucose tolerance [109], and altered
corneal development [82]. In corneal epithelial cells, BTC is more efficacious than EGF
in mediating wound healing [19]. Despite evidence that BTC enhances wound healing
under both physiological and pathological conditions, the molecular mechanism by
which BTC enhances this process is unclear. These data illustrate the long-standing,
inherent confusion regarding BTC-mediated signaling, and the need for a unifying
model.
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In this study, we found that BTC is a better mediator of cell migration than EGF,
despite a lower affinity for and reduced phosphorylation of the EGFR [110]. The
reduced receptor phosphorylation is due to the EGFR’s formation of heterodimers
with the kinase impaired ErbB3. Biochemical evidence for these heterodimers comes
from the ability of BTC to promote ErbB3 phosphorylation in the absence of ErbB2.
Cell biological evidence of EGFR:ErbB3 heterodimers is visualized with proximity
ligation assays. When ErbB3 signaling is antagonized or depleted using an ErbB3
antibody MM-121 [111] or siRNA, cell migration is reduced more in response to BTC
than EGF; further indicating BTC mediates migration through ErbB3. Together, these
data provide a new model in which a ligand can bias dimerization partners of the
EGFR and affect cell physiology [112].

Experimental Procedures
Cell lines – hTCEpi cells were obtained from Geron Corp. (Menlo Park, CA). Human
corneal epithelial cells were immortalized by the stable transfection of human
telomerase reverse transcriptase [113]. Cells were grown in growth media (Defined
Keratinocyte with growth supplement; Invitrogen, Carlsbad, CA) at 37°C and were
maintained at 5% CO2. MDA-MB-468 cells were acquired from the ATCC. Cells were
maintained in growth media [Dulbecco’s Modified Eagle Medium (DMEM)]
supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin, 1% streptomycin,
and 2 mM glutamine all acquired from Life Technologies (Grand Island, NY). Cells
were maintained at of 37 ºC in 5% CO2.
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Materials – EGF, BTC, and NRG4 were purchased from Prospec-Tany TechnoGene Ltd
(Rehovot, Israel). MM-121 (seribantumab) was a kindly provided by Merrimack
Pharmaceuticals, Inc, (Cambridge, MA) [111]. All other chemicals were purchased
from Sigma-Aldrich unless otherwise noted.
Single cell growth assay - hTCEpi cells were plated at a density of 30 cells/well in a 12
well tissue culture dish in low serum media (25% growth media and 75% serum free
media). Cells were grown to the eight cell stage then treated with EGF or BTC [1.6 nM]
or no ligand. Photographs of the cell colonies were taken every 24 hours. At each time
point, the number of cells per colony were counted and the area the colony covered
was measured using Image J software [114].
Competition binding – All radioligand binding experiments used binding buffer
(DMEM (without bicarbonate), 10mM NaHEPES, 0.1% BSA, pH 7.4). Confluent 12well dishes of hTCEpi cells were incubated with varying concentrations of cold ligand
(EGF, BTC, NRG4) and

125I-EGF

(Perkin Elmer Life Sciences, catalog no. NEX160;

specific activity 150-200 Ci/g, ~10,000 cpm/10μl). Cells were incubated on ice for
2 hours allowing a steady state binding while preventing membrane trafficking. Cells
were washed 4 times with radioligand binding buffer, solubilized in 0.1% SDS/0.1N
NaOH and radioactivity level of each sample was determined using a Beckman
Coulter gamma counter (Brea, CA). Data are plotted as the percentage of maximal
radioactivity as determined from cells with no competitive ligand added. IC50 values
were calculated using a one-site model using GraphPad Prism 5.0 (La Jolla, CA).
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pH dissociation binding – Confluent 12-well dishes of hTCEpi cells were incubated
with 125I-EGF or 125I-BTC (~10,000 cpm/10μl). Cells were incubated on ice for 2 hours
allowing a steady state distribution of the ligands. The pH of radioligand binding
buffer was adjusted with NaOH or HCl to bring the buffer to the desired pH (2 – 8).
pH-adjusted buffer was used to wash the cells to remove excess ligand and dissociate
the ligand from the receptor. Cells were solubilized in 0.1% SDS/0.1N NaOH and the
associated radioactivity in each sample was determined using a Beckman Coulter
gamma counter. Data are plotted as the average (± S.E.M.) percentage of radioactivity
relative to maximal binding.
Western blot with phospho-specific antibodies – hTCEpi cells were washed twice with
PBS pH 7.4 and incubated with serum-free KSFM for 2h. Cells were treated with the
indicated ligand concentration at the indicated time. Treated cells were subjected to
two quick washes with PBS pH 7.4, equilibrated to 4°C on ice. Cells were harvested in
RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM
Tris, pH 8.0, 10 mM sodium pyrophosphate, 100 mM sodium fluoride) supplemented
with 2 mM Phenylmethylsulfonyl fluoride (PMSF), solubilized with end over end
rotation for 10 min at 4°C. Insoluble material was removed by centrifugation for 10
min at 4°C and maximum speed (21,130 rcf) in an Eppendorf 5424R (Hamburg,
Germany). Equivalent amounts of cell lysate were resolved by SDS-PAGE and
transferred to nitrocellulose. The indicated proteins were immunoblotted using the
following antibodies: EGFR (SC-03) and EGFR (A-10) antibodies obtained from Santa
Cruz Biotechnology (Dallas, TX), site specific phospho-EGFR antibodies (pY992,
pY998, pY1045, pY1068, pY1148, and pY1173) were from Cell Signaling (Danvers,
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MA), -tubulin antibodies were from Sigma-Aldrich (St. Louis, MO). Following
incubation

with

the

appropriate

HRP-conjugated

secondary

antibody,

immunoreactive proteins were visualized with ECL and a Fotodyne Imaging system
(Hartland, WI).
Immunoprecipitations - Cell lysates (500 g, see “Western Blot”) were incubated with
either a pool of phospho-tyrosine antibodies (pY20, sc-508; pY99, sc-7020 from Santa
Cruz Biotechnology, Santa Cruz, CA and 4G10, 05-321 from EMD Millipore, Billerica,
MA) or ErbB3 antibodies (sc-285, sc-7390, sc-415, Santa Cruz Biotechnology, Santa
Cruz, CA)(HER3/ErbB3 (D22C5) XP, Cell Signaling) while rotated end over end at 4oC
overnight. Protein A/G agarose beads (Santa Cruz Biotechnology, Dallas, TX) washed
with RIPA buffer were added and rotated end over end at 4oC for 2 hours. Lysates
were centrifuged and a sample of the supernatant was kept as pass through (PT), the
rest discarded. Then, RIPA buffer was used to wash the beads three times. To elute
the protein from the beads, SDS sample buffer was added to the samples and heated
to 100◦C for three minutes. The immunoprecipitates were divided into thirds,
separated by SDS-PAGE, transferred to nitrocellulose, and detected with the indicated
antibody EGFR and PY99 (Santa Cruz Biotechnology, Dallas, TX); ErbB2 and ErbB3
(Cell Signaling); ErbB3 (Santa Cruz Biotechnology, Dallas, TX, Cell Signaling), as
described previously.
PLA Proximity Ligation Assay (PLA) - hTCEpi cells were plated on NaOH cleaned 12mm
round #1 coverslips in a 24-well plate and grown to 70-80% confluency. Serumstarved cells were treated with media, EGF (16 nM), or BTC (16 nM) at 37◦C for 15
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min. Coverslips were washed with PBS++ (PBS pH 7.4 /0.25 M CaCl2/0.25M MgCl2)
and fixed with 4% paraformaldehyde/PBS++ for 5 min on ice and 15min at room
temperature.

Cells were permeabilized with 0.1% saponin/0.5% fetal bovine

serum/PBS++ for 15 min, washed 3 times in PBS++. EGFR homodimers and
EGFR:ErbB3 heterodimers were detected using Proximity Ligation Assay kit
(DuoLink, Sigma Aldrich) according to manufacturer’s directions. Primary antibodies
EGFR (E114, RabMAb Abcam) and ErbB3 (2F12, Thermo Scientific) were used
independently and jointly as indicated in experiments. Fluorescence images and
quantification were acquired using a Nikon Eclipse Ti-E widefield microscope using
Nikon NIS Elements software (Nikon, Melville, NY).
Transwell migration assay - 100,000 hTCEpi cells in serum- free media (Keratinocyte
Defined Media without growth supplement, 100 L; Invitrogen) with or without 170
g/ml MM-121. were plated in the upper chamber of an 8 m polycarbonate
membrane, 6.5-mm insert (Corning, Inc., Corning, NY) for 2 hours at 37°C. Following
incubation, the lower chamber contained 600 L serum-free media containing the
indicated concentrations of growth factor with or without MM-121 (seribantumab, a
gift of Merrimack Pharmaceuticals, Cambridge, MA). Cells were allowed to migrate
for 16 hours at 37°C in 5% CO2. Migrated cells were determined by fixing the cells in
methanol, staining in Giemsa, and counting the migrated cells under a microscope
(TE-2000; Nikon, Tokyo, Japan) with a 60X objective[115].
siRNA – The siRNA were obtained from the following sources: scramble control siRNA
(siCON), EGFR and ErbB2 were acquired from IDTDNA (Coralville, IA), ErbB3 Silencer
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Select was acquired from ThermoFisher Scientific, Waltham, MA). hTCEpi cells were
transfected with the indicated siRNA by Amaxa electroporation as described
previously [116]. Cells were allowed to recover for 48 hours. Cells were assayed by
western blot for knockdown efficacy, phosphorylation of receptors or cell migration
as described in materials and methods.
Statistical analyses – Statistical tests are indicated in the figure legends and were
performed using GraphPad Prism 5.0 (La Jolla, CA).

Results
BTC induces more cell migration than EGF
Our previous studies identified BTC as a more efficacious mediator of in vitro
corneal epithelial wound healing than EGF [19]. Corneal epithelial wound healing is a
multi-faceted process that includes cell migration and proliferation [117]. The first
goal for understanding the molecular basis for BTC’s enhanced activity was to
determine if the ligand was augmenting cell migration, cell proliferation, or both
processes. To assess ligand effect on proliferation and migration, hTCEpi cells were
plated as single cells and cultured in media alone or media supplemented with EGF
or BTC. The same colony was photographed over 72 hours (Fig 4A). From these
images, the number of cells and their total area was determined (Fig 4B, 4C). Cells
grown in the presence of BTC covered a larger area of the dish as compared to those
grown in EGF or media alone indicating the BTC-treated cells were more migratory.
Importantly, treatment with EGF increased the number of cells.
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To supplement that assay, a Transwell assay was used to directly measure cell
migration in response to the growth factors (Fig 4D). BTC had a 6-fold increase in cell
migration as compared to 4-fold increase with EGF. Together, these assays
demonstrate that BTC more efficaciously promotes cell migration as compared to
EGF.

Figure 4. BTC is a more efficacious activator of cell migration than EGF. A-C) hTCEpi
cells were plated as single cells (30 cells/35 mm dish) in media alone, 1.6 nM EGF, or 1.6
nM BTC (Peterson, JL). A) Once cell colonies formed, they were imaged at 24 hour
intervals for 72 hours. Shown are representative data from an experiment repeated three
times (n= 3-4 experiments, ~25-70 colonies for each condition). Scale bar = 200 m. B)
Data from three separate experiments were plotted as average ± S.D. fold change as
number of cells per colony. C) Data from three separate experiments were plotted as
average ± S.D. fold change in area per cell. D) hTCEpi cell migration was measured using
a Transwell assay after migrating for 16 hours as described in Experimental Procedures
(Rush, JS). Cells were incubated in serum free media with no additions (Media), serum
(Serum), 1.6 nM EGF, or 1.6 nM BTC. Plotted are the fold changes in cell migration
(relative to serum free media) for each condition (n=6). Data were analyzed using a twoway ANOVA with Tukey’s post-hoc analysis. *= p<0.05 and ** = p<0.01.
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BTC binds EGFR with lower affinity.
BTC is universally accepted to bind both EGFR and ErbB4 [90, 118], but others
report that BTC can bind/activate ErbB2 and ErbB3 as well [87, 91]. hTCEpi cells do
not express ErbB4 [19], so we restricted our focus to the EGFR. To determine if EGF
and BTC were binding the same receptor, we performed an

125I-EGF

competition

binding assay. EGF, BTC, and Neuregulin 4 (NRG4) as a negative control, were used to
compete for radiolabeled EGF (Fig 5A). EGF (IC50= ~2 nM) was able to compete for
125I-EGF

binding with a 30-fold higher affinity than BTC (IC50= ~60 nM); 100 nM

NRG4 was unable to displace

125I-EGF

binding, consistent with its role as an ErbB4

specific ligand (Fig 5A). These data indicate that EGF and BTC compete for the same
binding site and BTC has a lower affinity for the EGFR.
Next, we examined whether EGFR binding of BTC and EGF, had differing
sensitivities to pH. As the ligand:receptor complex progresses through the endocytic
pathway, it moves through an increasingly acidic environment. Ligand binding is one
of the factors that determines if the receptor recycles back to the plasma membrane
or is targeted to the lysosome. Approximately 50% of bound 125I-EGF dissociated at
pH 5.8, whereas a pH of 4.3 was required to dissociate 50% of the bound 125I-BTC (Fig
5B). These values led to the prediction that ~50% of EGF:EGFR complexes will
dissociate in the early endosome [pH ~5.9-6.8 [119]], whereas, the BTC:EGFR is not
predicted to have appreciable dissociation, even in the lysosome [pH ~ 4.5-5.0 [119]].
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Figure 5. BTC and EGF bind EGFRs with different affinities and pH sensitivities. A)
125I-EGF competition binding using varying concentrations of EGF, BTC, or NRG4 as
indicated. B) pH sensitivity of 125I-EGF and 125I-BTC binding. Cells were incubated with
radioligand at pH 7.4 and 4C until steady-state binding was achieved. Cells were then
incubated in binding buffer at varying pH at 4C for 30 minutes, then washed three times
in ice cold buffer of the same pH. Cells were solubilized and associated radioactivity was
measured. For (A-B), data are plotted as the percent of maximal radioligand binding
(average ± S.D., n=3) (Peters JL).

BTC induces less EGFR phosphorylation but more ErbB3 phosphorylation
Consistent with the reduced affinity, BTC was a weaker activator of EGFR, as
compared to EGF. Using ligand concentrations that produced maximal cell migration
[19], a time course of tyrosine phosphorylation was used as a read-out of EGFR
activity (Fig 6). hTCEpi cells treated with BTC as compared to those treated with EGF
had reduced EGFR phosphorylation at all four of the tyrosine residues examined (Fig
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6A). Similar trends were observed in MDA-MB-468 cells, a metastatic breast cancer
cell-line with comparable levels of EGFR (Fig 7).

Figure 6. BTC is a less efficacious activator of EGFR phosphorylation in hTCEpi
cells. Cells were treated with 1.6 nM EGF or 1.6 nM BTC for the indicated times. Cell
lysates were prepared and immunobloted with the indicated EGFR phosphotyrosine
specific antibodies (pY998, pY1045, pY1068, pY1148), total EGFR, or -tubulin. A)
hTCEpi cell representative blots from three experiments (Peterson JL). B-F) Western
blots quantified using ImageJ software. Phosphotyrosine blots were normalized to the
30 min timepoint, total EGFR is normalized to untreated EGFR levels (Rush JS).
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Figure 7. BTC is a less efficacious activator of EGFR phosphorylation in MDA-MB468 cells. Cells were treated with 1.6 nM EGF or 1.6 nM BTC for the indicated times. Cell
lysates were prepared and immunobloted with the indicated EGFR phosphotyrosine
specific antibodies (pY998, pY1045, pY1068, pY1148), total EGFR, or -tubulin. A) MDAMB-468 cell representative blots from three experiments. B-E) Western blots from A)
were quantified using NIH ImageJ software. Data are presented as a ratio of each

treatment to the most abundant protein.
The decrease in EGFR phosphorylation led us to an alternative explanation. We
hypothesized that EGF promoted EGFR homodimers, whereas BTC preferentially
formed EGFR:ErbB3 heterodimers. The model accounts for the observation that 1)
the ligands can compete for binding with one another [53, 120], 2) the EGFR:ErbB3
heterodimers would have reduced EGFR phosphorylation due to ErbB3 being kinase
impaired [42], and 3) ErbB3 activation is associated with induced proliferation and
migration [121-123].
To test whether BTC could differentially signal through other ErbB receptors,
we examined receptor phosphorylation (Fig 8). hTCEpi cells were treated with media
alone, or media supplemented with EGF or BTC.

Denatured cell lysates were

immunoprecipitated with an anti-phosphotyrosine antibody and probed for the
presence of the three endogenous ErbB receptors (Fig 8A). BTC treatment led to
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decreased phosphorylation of EGFR and ErbB2 when compared to EGF, whereas only
BTC treatment resulted in significant ErbB3 phosphorylation (Fig 8D). Significant
ErbB3 phosphorylation by BTC was also observed when cell lysates were
immunoprecipitated using an ErbB3 antibody and immunoblotted with an antiphosphotyrosine antibody (Fig 8B, 8E).
hTCEpi cells were transduced using ErbB2-specific shRNA to examine the
possibility of ErbB2 involvement in ErbB3 phosphorylation.

BTC-mediated

activation of ErbB3 is unaffected by the loss of ErbB2 (calculated to be 86%
knockdown), further indicating that ErbB2 is dispensable in BTC activation of ErbB3
(Fig 8C, 8F). To determine whether these observations were specific to hTCEpi cells,
we treated MDA-MB-468 cells with EGF and BTC, and then immunoprecipitated
phosphorylated tyrosines and immunoblotted for the same three ErbB receptors
available in hTCEpi cells (Fig 9A-D). MDA-MB-468 cells express EGFR and ErbB3, but
do not express detectable levels of ErbB2 or ErbB4 [124](Figure 9A-D). As with the
hTCEpi cells, BTC treatment resulted in less EGFR tyrosine phosphorylation, and
induced ErbB3 tyrosine phosphorylation.
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Figure 8. BTC induces ErbB3 phosphorylation in hTCEpi cells without ErbB2
interaction. A-C) hTCEpi were treated with serum free media alone, 1.6 nM EGF, or
1.6 nM BTC for 15 min as indicated. Cell lysates were prepared under denaturing
conditions and the indicated proteins were immunoprecipitated using A) antiphosphotyrosine (Peterson JL), or B) anti-ErbB3 antibodies. The pass-through (PT) and
immunoprecipitates were resolved by 7.5% SDS-PAGE, and immunoblotted with the
indicated antibodies. Shown are representative blots from an experiment performed
at least three times. C) Transduced ErbB2-shRNA and shRNA control (materials and
methods) hTCEpi cells were treated the same as A-B. Shown are representative blots
from three replicates. D-F) Immunoblots from A-C were quantified using NIH Image J.
Data are presented as the average ratio (+ S.D.) of each treatment to the most abundant
protein. Blots were analyzed with a two-way ANOVA, Holm-Sidak’s multiple
comparisons test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 NS= not significant (Rush
JS).
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Figure 9. BTC induces ErbB3 phosphorylation in MDA-MB-468. A-B) MDA-MB-468
were treated with serum free media alone, 1.6 nM EGF, or 1.6 nM BTC for 15 min. Cell
lysates were prepared and proteins immunoprecipitated using A) anti-phosphotyrosine
or B) anti-ErbB3 antibodies. The pass-through (PT) and immunoprecipitates were
resolved by 7.5% SDS-PAGE, and immunoblotted with the indicated antibodies. Shown
are representative blots from an experiment performed at least three times. C-D) Blots
were analyzed with a two-way ANOVA, Holm-Sidak’s multiple comparisons test.
Normalized experiments are presented as ratios compared to the strongest band for each
blot, * = p < 0.05, ** = p < 0.01, *** = p < 0.001 NS= not significant (Rush JS).

BTC promotes ErbB3 phosphorylation and EGFR:ErbB heterodimers
These biochemical data provide evidence that BTC causes ErbB3
phosphorylation, but do not demonstrate a direct interaction. Another possibility is
ErbB3 phosphorylation is mediated by a non-receptor kinase that is activated by the
liganded EGFR. To determine if BTC caused an increase in EGFR:ErbB3 heterodimers,
we performed proximity ligation assays (PLA) (Fig 10). PLA is an antibody based
detection/amplification system that will reveal protein:protein interactions when
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they are within 40 nm. hTCEpi cells were treated with media alone, or media
supplemented with EGF or BTC, fixed and subjected to the PLA protocol (see
Experimental Procedures). When cells were screened for the presence of EGFR:ErbB3
heterodimers, EGF produced a 1.1 fold increase in heterodimers, and BTC produced
a 2.6-fold increase (Fig 10B). Together, the receptor phosphorylation data and the
PLA support the notion that EGF treated cells have less EGFR:ErbB3 heterodimer
interactions when compared to those treated with BTC.
Finally, we wanted to determine if the EGFR:ErbB3 heterodimers were
responsible for the increase in cell mobility that was seen with BTC treatment. We
monitored ligand-dependent cell migration using a Transwell migration assay in the
absence and presence of the ErbB3 antagonist antibody, MM-121 (seribantumab)
[111] (Fig 11A). MM-121 treated cells migrate similarly with media alone, serum or
EGF. In contrast, in the presence of MM-121, BTC treated cells no longer migrated
more than EGF treated cells.
To determine the contribution of ErbB family members on BTC-mediated
migration, we knocked down EGFR, ErbB2, and ErbB3 (Fig. 11B) individually.
Transfection of hTCEpi cells with these siRNA attenuated expression of EGFR, ErbB2
and ErbB3 by 49%, 78% and 91% respectively. The decreased levels of ErbB3
eliminated the significant BTC mediated migration advantage when compared to EGF
(Fig. 11C). The loss of any of the three ErbB RTKs decreases the efficacy advantage of
BTC treatments over EGF (Fig. 11C). These data are consistent with all ErbB family
members contributing to BTC-mediated signaling.
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Figure 10. BTC induces EGFR:ErbB3 heterodimers in hTCEpi cells. EGFR:EGFR or
EGFR:ErbB3 dimerization was visualized by proximity ligation assay (PLA). After serum
starving cells for 2 hrs, hTCEpi cells were treated with serum free media alone or with
16nM EGF or BTC for 15min at 37◦C. After treatment, cells were fixed and probed using
the proximity ligation assay (PLA) as described in Material and Methods. Representative
micrographs of cells probed for A) EGFR:ErbB3 heterodimers. Data from three
independent experiments were quantified (50-100 cells/experiment) and are presented
as the total number of signals per cell (B) and analyzed with a one-way ANOVA, HolmSidak’s multiple comparisons test. Normalized experiments are presented as the number
of signals compared to untreated (C), and quantification were analyzed with an unpaired
student’s t-test. * = p < 0.05 (Rush JS).
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Figure 11. ErbB3 antagonist MM-121 and knockdown inhibit BTC-mediated
migration to a greater extent than EGF-mediated migration. A) hTCEpi cells were
plated on the upper chamber of transwells (0.8 nm pore) and pre-treated without or
with 170 g/ml MM-121 for 2 hours. The media was replaced with 1) serum free media
alone, 2) EGF (1.6 nM) or 3) BTC (1.6 nM) in the absence or presence of MM-121. Cells
were incubated for 16 hours and migration to the lower chamber was measured by
counting the number of migrated cells on the underside of the membrane. Shown are
the results of 6 independent experiments for each condition. B) hTCEpi cells were
transfected with either control siRNA (siCON) or siRNA specific for EGFR, ErbB2 or ErB3
as described in Materials and Methods. After recovery (72h), B) immunoblots from cell
lysates were prepared from hTCEpi samples, and equal amounts of total protein loaded.
Samples were resolved by SDS-PAGE and immunoblotted with the indicated antibody.
Immunoblots shown are representative from experiments performed at least 6 times.
C) transwells were loaded with transfected cells as described in Materials and Methods.
Migrated cells were quantified and each experiment normalized to media treated cells
independently. Each y-axis indicates a different transfected hTCEpi cell-line. The results
are plotted as mean + S.D. Data were analyzed with a two-way ANOVA with Holm-Sidak’s
post-hoc analysis, * = p < 0.05, NS= not significant (Rush JS).
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Discussion
In this manuscript, we demonstrate that EGFR-related growth factors differ in
their ability to induce phosphorylation, direct specific receptor dimerization and
effect cell physiology. Multiple labs have reported that BTC is more efficacious than
EGF [19, 90, 111, 125]. We show that in line with ligand efficacy, BTC enhances cell
migration more than EGF (Fig 4 and 11), which is a fundamental component of
corneal wound healing (Fig 4 and 11). Furthermore, this effect is not due to enhanced
BTC binding to or phosphorylation of the EGFR (Fig 5 - 7), as these responses are
reduced with BTC treatment. Rather, BTC binding to the EGFR biases the receptor to
heterodimerize with ErbB3, resulting in ErbB3 phosphorylation (Fig 5-10).
Importantly, BTC-mediated ErbB3 phosphorylation is independent of ErbB2. These
heterodimers are more efficacious mediators of cell migration, as ErbB3 antagonists
and knockdown inhibits BTC-mediated migration to a greater extent than EGFmediated migration (Fig 10).
We propose a model in which EGF and BTC both bind the EGFR, but
differentially bias the dimerization partner of the ligand-bound receptor. This ligandbiased signaling is known among G-protein coupled receptors [126-128]. In the cell,
monomeric ErbB RTKs and their ligands are in a biochemical equilibrium. The
binding of ligand shifts the equilibrium of the receptors from a monomeric to a
dimeric form. Our data here support a model in which the ligand:EGFR directs
whether the dimers are homodimers or heterodimers. There is an additional layer of
complexity to this model when applying it to other cell lines that express the ErbB
RTKs at different levels.
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Reports in the literature have been inconsistent regarding how BTC induces
ErbB3 phosphorylation [118, 129-132]. We postulate that the variability in the
absolute and relative amounts of EGFR and ErbB3 are a potential source for these
discrepancies. Since BTC drives the formation of EGFR:ErbB3 heterodimers, if EGFRs
are in vast excess, once the maximum number of heterodimers are formed, the
remaining liganded EGFRs are able to form homodimers or ErbB2 heterodimers. Our
data support this hypothesis, as the loss of EGFR and ErbB2 also decreased the
significant advantage BTC treatment had on migration (Fig 11). hTCEpi cells have
sufficient levels of EGFR and ErbB3 that produce functional EGFR:ErbB3
heterodimers, as evident by the decreased cell migration in response to ErbB3
antagonist and ErbB3 knockdown. Cells that do not express ErbB3 may not show
differences in responses to EGF and BTC migration.
Several previous studies support this model. First, Liu et al. report that a single
ligand is sufficient to activate EGFR dimers [61]. While this is well accepted for ErbB
RTKs that heterodimerize with the ligandless ErbB2, it is important to note that it can
extend to the other family members that undergo conformational changes to
dimerize. Second, our findings that receptors preferentially form dimer partners is
supported by the work of MacDonald-Oberman et al. [120, 133]. Our endogenous
receptor model proposes that these preferences can be shifted by the activating
ligand. As indicated from our PLA experiments, BTC preferentially drives the
formation of EGFR:ErbB3.
It was fortunate that hTCEpi and MDA-MB-468 cells do not express ErbB4,
another target for BTC binding. With the addition of ErbB4, the model would have to
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take into consideration the binding affinities for EGFR versus ErbB4. Although ErbB2
does not bind BTC, its contribution cannot be overlooked. It is likely that ErbB2 is
also competing for binding to the liganded EGFRs. ErbB3 phosphorylation was
unaffected by the loss of ErbB2, further supporting EGFR as the sole ligand binding
receptor in our system. The incomplete inhibition of ErbB3 initiated migration in
response to MM-121 may be due to compensatory ErbB2 effects. The knockdown of
each ErbB RTK had an increase in protein levels of the other ErbB RTKs when
compared to control lysates (data not shown), especially with EGFR knockdown (Fig.
11C). Other groups show that compensatory protein effects following knockdown of
similar proteins are possible and support this phenomenon [134-136]. This effect
was also supported in the receptor knockout cell lines where the loss of EGFR, ErbB2
and ErbB3 decreased the migration advantage BTC has over EGF. While ErbB2 is not
necessary to activate ErbB3 with BTC, it contributes to BTC-mediated migration, like
ErbB3 (Fig 11B). More rigorous mathematical modeling and experimentation are
required to account for the complexities of the entire ErbB RTK family.
While it has been previously appreciated that ligands can direct dimer
formation, it was largely attributed to differences between which receptor and the
ligand bound [120]; our model proposes that two different ligands are binding the
same receptor, but forming different heterodimer populations. How would ligand
binding direct the dimerization partner? One possibility is that human EGF and BTC
have limited sequence similarity (~36%) as well as low predicted three-dimensional
structural homology as measured by solvent accessibility surfaces [108].
Alternatively, the size of the ligand may affect receptor conformation. The processed
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form of BTC is 9 kDa and EGF is 6.6 kDa [46]. A stretch of ~50 amino acids directly
binds to the ligand-binding domain of the receptor [137]. The size and/or charge of
the remaining 30 amino acids may sterically hinder BTC:EGFR homodimerization.
Fundamental differences in binding are supported by our observed differences in
radioligand competition binding and pH sensitivity for the two ligands (Fig 5).
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CHAPTER III
BTC INDUCES DIFFERENTIAL EGFR TRAFFICKING AND COMPARABLY ACTIVATES
AKT AND MAPK
Introduction:
Many tissues throughout the body express EGFR. Once ligand binds the
receptor, the receptor becomes activated intracellularly and is then able to activate
effectors (i.e. Shc, Grb2, c-Cbl, MAPK, AKT). The activities of these EGFR activated
effectors modulate receptor trafficking and ultimately, cell physiology.

EGFR

activation is known to alter cell survival, proliferation, differentiation and migration.
These cellular changes then translate to functional changes in tissue development,
wound healing, tissue maintenance and cancer biology [138, 139].
The clathrin-mediated endocytic pathway is the primary molecular
mechanism that balances EGFR signaling and regulation [140]. Ligand bound ErbBreceptors internalize via clathrin-coated pits and initiate the activation of
downstream signaling pathways. The cargo, now inside the cell, travels through the
endocytic pathway by moving from clathrin-coated vesicles to early endosomes,
which mature to late endosomes/multivesicular bodies and finally to the lysosome
for degradation. This process typically attenuates the EGFR signaling adequately,
although the complete mechanisms remain unclear due to the complexity of this
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process. Some possible EGFR regulatory mechanisms include dephosphorylating the
receptor, sequestering the receptor (decreasing effector interaction), ubiquitylation,
and relocation of the receptor from the plasma membrane [141].
This study examines changes in receptor trafficking and downstream effectors
in response to EGFR ligands EGF and BTC. Although we found BTC significantly
increases 1) ErbB3 phosphorylation, 2) EGFR:ErbB3 interactions, 3) migration rates
4) EGFR trafficking rates in corneal cells, there was no measurable change in
downstream effector signaling relative to the differences when compared to EGF. We
did identify that downstream signaling between EGF and BTC was similar, despite
having decreased phosphorylation of the binding receptor, EGFR. This finding
indicates that other effectors/pathways are involved in EGF/BTC associated
physiology changes, not trafficking.
Experimental Procedures
Cell Lines- hTCEpi cells were obtained from Geron Corp. (Menlo Park, CA). Human
corneal epithelial cells were immortalized by the stable transfection of human
telomerase reverse transcriptase [113]. Cells were grown in growth media (Defined
Keratinocyte with growth supplement; Invitrogen, Carlsbad, CA) at 37°C and were
maintained at 5% CO2. HeLa cells were a gift of Sandra Schmid (The Scripps Research
Institute) and were maintained in Dulbecco’s Minimal Essential Media (DMEM)
containing 5% fetal bovine serum (FBS), 100 units/mL penicillin, 100mg/mL
streptomysin, and 2 mM glutamine. Cell lines were maintained at 37◦C in 5% CO2.
Percoll Gradient Fractionation—Analysis of radioligand distribution was performed
as described by Kornilova et al. (10). Briefly, hTCEpi cells were incubated for 15 min
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with 125I-EGF or BTC (1ng/ml) at 37 °C in binding buffer (DMEM, 20 mM HEPES, 0.1%
bovine serum albumin (pH 7.4)). Following treatment, cells were washed three times
with PBS and returned to 37 °C in growth media. After another 30,45,105 min
(45,60,120 min total), cells were washed twice with TES [10 mM triethanolamine, 1
mM EDTA, 0.25M sucrose (pH 7.2)] and harvested in 2 ml of TES. Lysates were
pipetted up and down 40 times and centrifuged for 10 min at 200 x g in a Sorvoll
JA25.5 rotor. The supernatant was transferred to a clean tube and the pellet was
resuspended in 2 ml of TES and centrifuged again. The resulting 4 ml of postnuclear
supernatant was diluted with a 90% Percoll solution in TES to 17% in 11.5 ml.
Samples were centrifuged for 25 min at 4 °C at 50,000 g in a Beckman Ti65 rotor to
separate early and late endocytic compartments. Samples were fractionated into 10drop fractions (30 fractions/gradient) from the bottom and measured for
radioactivity in a Beckman counter. Data are plotted as the percentage of total
radioactivity in each tube versus the relative migration of each fraction in the sample.
Density was monitored using density marker beads (Amersham Biosciences).
Western Blotting - hTCEpi cells were washed twice with PBS pH 7.4 and incubated
with serum-free KSFM for 2h. Cells were treated with 1.6 nM EGF or BTC for 15, 30,
60, 120, 240 min. Treated cells were subjected to two quick washes with PBS pH 7.4,
equilibrated to 4°C on ice. Cells were harvested in RIPA buffer (150 mM NaCl, 1%
Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, 10 mM sodium
pyrophosphate,

100

mM

sodium

fluoride)

supplemented

with

2

mM

Phenylmethylsulfonyl fluoride (PMSF), solubilized with end over end rotation for 10
min at 4°C. Insoluble material was removed by centrifugation for 10 min at 4°C and
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maximum speed (15,000 g) in an Eppendorf 5424R (Hamburg, Germany). Equivalent
amounts of cell lysate were resolved by SDS-PAGE and transferred to nitrocellulose.
The indicated proteins were immunoblotted using the following antibodies: EGFR
(SC-373746) antibodies obtained from Santa Cruz Biotechnology (Dallas, TX), site
specific phosphoEGFR antibody (pY1045), total AKT (9272, phospho-AKT, Ser473
(4051), MAPK 42/44 (4695), phospho-MAPK 42/44 (9101) from Cell Signaling
(Danvers, MA), -tubulin antibodies were from Sigma-Aldrich (St. Louis, MO).
Following incubation with the appropriate HRP-conjugated secondary antibody,
immunoreactive proteins were visualized with ECL and a Fotodyne Imaging system
(Hartland, WI).
Results
EGFR Trafficking Accelerated with BTC Treatment
To determine whether physiological effects of ligand treatment in hTCEpi cells
is related to changes in EGFR trafficking, we quantitatively examined 125I-EGF:EGFR
and 125I-BTC:EGFR endosomal distribution. Cells were treated with 125I-Ligand and
chased with radioligand-free media (materials and methods).

Early and late

endosomes were resolved using sedimentation velocity centrifugation from cell
lysate using 17% Percoll gradients. Density beads were used to verify the identity of
the fractions. Low density fractions (Rf ~0.3, 1.040 g/mL) correspond to early
endosomes and higher-density fractions (Rf ~0.9, =1.080-1.109 g/mL) correspond
to late endosomes [142].
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The distribution of radioactivity in cells treated with either

125I-EGF

or

125I-

BTC revealed similar trafficking and distribution of both ligands. In HeLa cells less
than 50% of the starting amount of 125I-EGF radioactivity remained at 120 minutes,
with minor peaks at densities corresponding to early and late endosomes (Fig. 12A).
Repeating the experiment using hTCEpi cells, less than 78% of the radioactivity after
15 min. of treatment remains at 120 min. (Fig. 12B). Then, hTCEpi cells were treated
with

125I-BTC

for 120 min. with only 28-32% radioactivity remaining (Fig. 12C).

Our biochemical data indicate that EGF and BTC trafficking is similar, in that
there is no apparent accumulation in the various compartments. However, BTC
passes through the endocytic pathway at a faster rate.
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Figure 12. 125I-EGF and BTC Traffic Differentially- The endocytic trafficking of the
125I-EGF:EGFR in Hela (A) and hTCEpi (B) and 125I-BTC:EGFR complex in hTCEpi cells
(C) was assessed by pulse-labeling cells with 125I-Ligand. Following a 7 min. ligand
treatment followed by radioligand-free media, post-nuclear supernatant was prepared
at 15, 45 or 60, and 120 min. Data were plotted as the relative distribution of 125I in each
fraction and were normalized to the total radioactivity. Circles along the x-axis indicate
the distribution of density beads (from lowest to highest Rf ~0.30=1.040 g/mL,
0.85=1.055 g/mL, 0.88=1.069 g/mL, 0.89=1.080 and 0.92=1.109 g/mL). Early
endosomes migrate at 1.035-1.042 g/mL. The heavier late endosomes sediment with a
density of 1.048-1.060 g/mL.

EGF and BTC Initiated AKT and MAPK Signaling Pathways are Indistinctive
The endocytic pathway is well regulated, and activation and downregulation
of receptors is balanced to control signaling pathways and maintain normal cell
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biology. Ligand activation of EGFR initiates signaling cascades involving multiple
proteins and pathways. The physiological consequences of the activation of the
various pathways are dependent on how, when and where proteins are activated or
deactivated (downregulated), and potentially, which ligand initially binds to the
receptor. To test that the physiological changes associated with BTC activation are
due to differences in the two main proliferation/migration signaling pathways, ligand
time course with both ligands was used to assess phosphorylation levels of AKT
(Ser473) and MAPK.
Serum starved hTCEpi cells were treated with or without 1.6 nM EGF or BTC
for 0-240 min., and total and phosphorylated EGFR, AKT (Ser473) and MAPK (42,44)
was measured by immunoblot analysis (Fig. 13A-C). Densitometric analysis using
ImageJ to quantify the difference in total phosphorylation relative to total protein
(Fig. 13B, C).

We observed unexpected indistinguishable activation of

proliferation/migration signaling pathways.

BTC induces comparable levels of

activation of both AKT and MAPK compared to EGF, even though BTC induces less
EGFR phosphorylation and increased ErbB3 phosphorylation.

47

Figure 13. EGF and BTC have comparable effector signaling- Cells were treated with
1.6 nM EGF or 1.6 nM BTC for the indicated times. Cell lysates were prepared and
immunobloted with the indicated EGFR phosphotyrosine 1045, total EGFR, phosphoAKT(Ser473), total AKT, phospho-MAPK (42/44), total MAPK (42/44) or -tubulin. A)
hTCEpi cell representative blots from three xperiments. B) Western blots quantified using
ImageJ software. Phospho-blots were normalized to the corresponding total.

Discussion
We have demonstrated previously that BTC induces migration more efficiently
than EGF in immortalized human corneal epithelial cells [19]. In a previous study
(Chapter II), we demonstrated that BTC induces increased signaling of ErbB3 and
heterodimers of EGFR and ErbB3. From the data, we developed the hypothesis that
increased effector signaling from ErbB3 or changes in trafficking would precede BTC
induced enhanced migration.
To test this hypothesis, we used hTCEpi cells and monitored EGFR endocytic
trafficking

125I-EGF

and BTC.

expect a decrease in total

125I

If the rate of EGFR trafficking increases, we would
over time; if trafficking slows, overall radioactivity

levels would increase, as well as the amount of 125I at the density regions associated
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with early or late endosomes. We observed similar trafficking between HeLa and
hTCEpi cells treated with
hTCEpi cells treated with

125I-EGF,
125I-BTC

with some experimental variability. However,

showed <3 fold difference in total radioactivity

after remaining at 120 min, when compared to EGF. Visually comparing Hela (Fig.
12A) and hTCEpi cells (Fig. 12C) at 60 min., you can see a well-defined peak in hTCEpi
cells in the region associated with early endosome densities. However, the Hela cells
at this same time point show small peaks in early and late endosomal regions and an
overall accumulation of 125I-EGF compared with 125I-BTC. This indicates that BTC is
processing through the late endosome at a faster rate. We showed previously that
EGF dissociates from EGFR at a higher pH than BTC, allowing BTC to stay bound
longer to EGFR throughout the endocytic pathway. These data support a model
where BTC can stay bound longer to the receptor, but does not apparently change the
kinetics of ligand:receptor trafficking based on Percoll gradients. Instead, when the
trafficking data and receptor degradation data are combined, the complex seems to
be trafficking through the endocytic pathway at a slightly faster rate, as supported by
other publications [66, 143].
MAPK and AKT are well known pathways associated with regulating
the migration and proliferation of cells [144-146]. ErbB3 has seven known direct
binding sites for PI3-kinase, an upstream activator of the AKT pathway.

We

hypothesized that BTC induced phosphorylation of ErbB3 would cause an increase of
AKT activity when compared to EGF treatment. We used immunoblotting to examine
phosphorylation patterns and unexpectedly, we saw comparable, at times
indistinguishable signaling patterns from both ligands. This data suggests that even
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though BTC has decreased activation of EGFR, downstream signaling is comparable,
from heterodimer-initiated pathways.
EGFR overexpression, hyperactivation and mutations in several types of
cancers is associated with poor patient prognosis [147]. This connection to disease
is harmonious with the receptor’s ability to induce cell proliferation, migration,
differentiation and viability. Hyperactivation of EGFR related to disease makes EGFR
a logical pharmacological target for cancer therapies including humanized
monoclonal antibodies (mAb) and small molecule kinase inhibitors. mABs block the
activation of the receptor by ligand binding, while TKIs bind the kinase domain and
prevent receptor signaling. While both types of EGFR inhibitors prove to be effective
at suppressing tumor growth in the short term, most patients acquire resistance. In
addition, patients using EGFR inhibitor therapy experience colitis, diarrhea,
dermatitis, and persistent corneal erosions. A deeper knowledge of EGFR:ErbB
trafficking, effector activation is needed to make drugs that are more effective with
less side effects and resistance. It has been suggested that compensatory networks
(heterodimers, increased protein expression, etc.) could be one reason resistance
occurs at such a high rate.
A deeper understanding and broader knowledge of EGFR trafficking and
signaling is needed to expand and improve targeted therapies. This study provides
evidence that two EGFR ligands that bind the same receptor can traffic differentially
and signal comparably even with diverse activation of the binding receptor.
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CHAPTER IV
SUMMARY AND CONCLUSIONS
The EGFR and the ErbB-family of receptors form a complex signaling network
with twenty-four possible ErbB-receptor combinations directed by eleven different
ligands. Since the initial discovery of EGF ligand in the 60s by the Cohen group,
researchers have elucidated some of the basic mechanics of receptor and ligand
binding possibilities, but how ligand choice and dimer pairing effects signaling
networks and cell physiology remains unclear. Examining the migration rate changes
of two ligands (EGF and BTC) bound to one ErbB-receptor (EGFR) preempted this
study of ligand-initiated mechanisms. Using hTCEpi cells, void of ErbB4, and limiting
our study to two ligands that only bind EGFR, we were able to deduce a few basic
mechanisms that are involved in BTC enhanced migration.
We discovered that even though BTC has decreased activation of EGFR at
equal concentrations to EGF, it is able to activate more EGFR:ErbB3 heterodimers and
consequentially phosphorylate more ErbB3. The phosphorylation of ErbB3 by BTC
could be the reason both EGF and BTC comparably activate the MAPK/AKT pathways,
even without comparable phosphorylation of EGFR. Both EGFR and ErbB3 have
receptor specific binding to effectors important for cell proliferation and migration.
ErbB3 has seven known direct binding sites for phosphatidylinositol-3-kinase (PI3K),
where EGFR has no direct PI3K sites, but can activate PI3K through two Grb2 binding
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sites. Even though Grb2 can also activate PI3K, ErbB3 has more binding potential
with PI3K, a known activator of mTOR and AKT pathways. Both mTOR and AKT are
important components of the proliferation and migration mechanisms in cell biology.
ErbB2:ErbB3 dimer pairings have been associated with proliferation and
migration, some studies showing one without the other inhibits migration. In our
study, we saw that ErbB3 is activated by BTC, even without the availability of ErbB2.
However, the loss of any of the ErbB-family of receptors in the hTCEpi cells limited
the enhanced migration advantage BTC has compared to EGF. This indicates that
while BTC has the potential to activate unique signaling pathways associated with
ErbB3 phosphorylation, without the ability to bind EGFR or ErbB2, physiological
advantages are limited or void.
Because EGFR is spatially and temporally regulated, cell physiology changes
are partially the result of how, where and how quickly EGFR traffics. When we
compared

125I-EGF

and

125I-BTC,

we found that the receptor did not appear to

accumulate in distinct endocytic compartments. However, when total radioactivity
changes between 15 min. and 120 min., BTC progressed through the endocytic
pathway at a noticeably faster rate. We also saw that BTC remained bound to EGFR
at a lower pH level than EGF, allowing the receptor to continue to signal throughout
the endocytic pathway. When the receptor complex remains activated throughout
endocytosis, the opportunity to interact with more downstream effectors increases,
ultimately effecting cell physiology like migration and proliferation.
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While this study only reveals a small part of the mechanisms involved in
ligand-initiated cell migration and wound healing by EGFR and two of its ligands, it is
an important step in simplifying the complex story of receptor regulation by ligand
specification.
Limitations of This Work
hTCEpi cells endogenously express three of the four ErbB-receptors. Their
ErbB-receptor’s ability to heterodimerize with each other and activate by binding to
nine different ligands, creates an overlapping spider web of activation, deactivation,
downregulation and recycling. This network of differential signaling limits how many
comparisons you can perform at one time and requires careful experimental design
to limit confusion and focus analysis. Direct comparison between a limited number
of receptors and ligands that only bind one receptor is the best way is to compare
ligands.

However, pharmacological inhibition can have off target effects and

knockdown can lead to compensatory production or increased activity of relative
proteins. Choosing cell lines that endogenously express a physiologically relevant
number of receptors would be ideal, as that would ensure studying a biological
process. However, not every cell line has known receptors or receptor densities, and
analysis to deduced receptor concentrations in a variety of cells would be
insurmountable.
Another limitation to this study is the lack of quality human specific antibodies
to analyze phosphorylation levels of many of the effectors associated with
proliferation and migration in the EGFR signaling pathway. PI3K is a critical regulator
of the migration pathway, but human specific antibodies for phosphorylated PI3K
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proteins are currently not available. Often, a

32P-ATP

assay is used to assess PI3K

activity following ligand activation, but this is a multi-step process that requires the
right equipment and expertise to analyze the assay effectively.
Strengths of This Work
A major strength of this work is the study focuses on the basic biology related
to a physiologically important process, cell migration. The basic mechanism assay
(receptor phosphorylation/PLA) results reveal molecular interactions that are
quantifiable and translatable to other cells lines besides cornea epithelial cells.
The in vitro cultivation of cell lines derived from the corneal epithelium has
become a powerful technique for research. It is also important to note that using a
substitute animal model used to assay drugs and other compounds is ethically
responsible. While it is still required to test new drugs and compounds in vivo,
performing research in an in vitro model can decrease the number and duration of
animals used in a study.
Future Directions
The study of EGFR activation, regulation and signaling continues to be
important for wound healing, cancer screening, regulation of cancer drug side effects
and EGFR targeted therapies. Even though a thorough understanding of individual
receptor mechanics is available, the impact of ligands and dimer pairings is still
unclear. Can a ligand be clinically useful to improve the quality of wound healing
while also decreasing the time to heal? A comprehensive study looking at ligand
binding, receptor dimers and effectors collectively would clarify the contributions of
each of the EGF-like ligands. Looking at receptors systematically in cell lines that
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endogenously contain certain ErbB rectors can eliminate some of the complexities
without interrupting the normal cell function. A large-scale study of ErbB receptors
in a variety of cells from multiple tissue types, normal and cancerous, would afford
researchers the opportunity to choose cell lines with specific receptor qualities and
document physiology changes after ligand activation. Multiplex assays have become
more mainstream, but the expense of the equipment and the price of consumables
associated with the assay have limited the scope of its contribution to ErbB receptor
signaling. Multi-plex assays that could analyze the phosphorylation of every known
effector would allow for direct comparison between ligand effects on the signaling
pathways. Being able to analyze at multiple time points would be cumbersome, but
necessary as effectors are activated at different times during endocytosis.
A much deeper understanding the effectors involved in BTC induced cell
migration can not only be helpful to produce new treatments for corneal wounds, but
also be relative to cancer therapies that target EGFR, EGFR signaling and manipulate
receptor agonist/antagonist. BTC overexpression has been associated with certain
cancer types, and using the data acquired from this study, you can see the possible
contribution of BTC in EGFR inhibitor resistance.
The individual contributions of all of the ErbB-receptor ligands, and how
dimer-pairing choice initiates downstream effectors, is critical to formulating new
treatments for corneal wound healing.

Just as important as quality of life

improvements with rapid wound repair, is answering the question of how
receptor/ligand choice can circumvent receptor knockdown and inhibition.
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